Search Videos and More
News
Dana-Farber Research Publication 8.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 through July 31.
News
FDA Approves New Therapy for Glioma Patients for First Time in Decades
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.
News
Dana-Farber Research Publication 8.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.
News
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention
Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
News
Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy
Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
News
Bringing Advanced Medicines for Multiple Myeloma into Reach for All
Multiple myeloma is a cancer of the bone marrow. It affects plasma cells, which are mature forms of blood cells called B-lymphocytes.
News
In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer
In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors.
News
U.S. News & World Report names Dana-Farber Brigham Cancer Center Among Nation’s Best for 2024-2025
For the 24th consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report.
News
Dana-Farber Research Publication 07.15.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Specially Equipped Natural Killer Cells Show Effectiveness Against the Most Common Form of Ovarian Cancer
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer
News
Jose Cancelas Named Director of the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute
Jose Cancelas, MD, PhD, recently joined Dana-Farber Cancer Institute as the director of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF).
News
Researchers Customize AI Tools for Digital Pathology
Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a relatively new field that uses high-resolution digital images that are created from tissue samples to diagnose diseases and inform treatment decisions.